Evidence map›Paper›PMID 33556128›Full record

ArticlePloS one2021

Clinical significance of potential drug-drug interactions in a pediatric intensive care unit: A single-center retrospective study.

Yu Hyeon Choi, In Hwa Lee, Mihee Yang, Yoon Sook Cho, Yun Hee Jo, Hye Jung Bae, You Sun Kim, June Dong Park

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. PregMedNet: Multifaceted Maternal Medication Impacts on Neonatal Complications.medRxiv : the preprint server for health sciences · 2025
    Article
  4. Article
  5. Article
  6. DDI-CYP: Metabolism ensemble models for drug-drug interaction predictions.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Evaluation of off-label medication use and drug safety in a pediatric intensive care unit.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yu Hyeon ChoiDepartment of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-3057-0886
In Hwa LeeDepartment of Pharmacy, Seoul National University Hospital, Seoul, Korea.
Mihee YangDepartment of Pharmacy, Seoul National University Hospital, Seoul, Korea.
Yoon Sook ChoDepartment of Pharmacy, Seoul National University Hospital, Seoul, Korea.
Yun Hee JoDepartment of Pharmacy, Seoul National University Hospital, Seoul, Korea.
Hye Jung BaeDepartment of Pharmacy, Seoul National University Hospital, Seoul, Korea.
You Sun KimDepartment of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
June Dong ParkDepartment of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0001-8113-1384
Seoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high prevalence of potential drug-drug interactions in pediatric intensive care units, their clinical relevance and significance are unclear. We assessed the characteristics and risk factors of clinically relevant potential drug-drug interactions to facilitate their efficient monitoring in pediatric intensive care units. This retrospective cohort study reviewed the medical records of 159 patients aged <19 years who were hospitalized in the pediatric intensive care unit at Seoul National University Hospital (Seoul, Korea) for ≥3 days between August 2019 and February 2020. Potential drug-drug interactions were screened using the Micromedex Drug-Reax® system. Clinical relevance of each potential drug-drug interaction was reported with official terminology, magnitude of severity, and causality, and the association with the patient's clinical characteristics was assessed. In total, 115 patients (72.3%) were exposed to 592 potential interactions of 258 drug pairs. In 16 patients (10.1%), 22 clinically relevant potential drug-drug interactions were identified for 19 drug pairs. Approximately 70% of the clinically relevant potential drug-drug interactions had a severity grade of ≥3. Exposure to potential drug-drug interactions was significantly associated with an increase in the number of administrated medications (6-7 medications, p = 0.006; ≥8, p<0.001) and prolonged hospital stays (1-2 weeks, p = 0.035; ≥2, p = 0.049). Moreover, clinically relevant potential drug-drug interactions were significantly associated with ≥8 prescribed drugs (p = 0.019), hospitalization for ≥2 weeks (p = 0.048), and ≥4 complex chronic conditions (p = 0.015). Most potential drug-drug interactions do not cause clinically relevant adverse outcomes in pediatric intensive care units. However, because the reactions that patients experience from clinically relevant potential drug-drug interactions are often very severe, there is a medical need to implement an appropriate monitoring system for potential drug-drug interactions according to the pediatric intensive care unit characteristics.

Indexed as

Drug MonitoringIntensive Care Units, PediatricLength of StayAdolescentChildChild, PreschoolDrug InteractionsFemaleHumansInfantInfant, NewbornMalePharmaceutical PreparationsRepublic of KoreaRetrospective StudiesPharmaceutical Preparations

Identifiers

PMID33556128
PMCPMC7870058
OpenAlexW3127940037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.